title: Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.
abstract: Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including chemotherapy, surgery, external beam radiation therapy, and radioisotopes, among others, have been recommended and utilized for palliative treatment of bone metastases. Radioisotopes such as samarium-153 are commonly used in the setting of multifocal bone metastases due to their systemic distribution, affinity for osteoblastic lesions, acceptable toxicity profile, and convenience of administration. This review focuses on samarium-153, first defining its radiobiologic and pharmacokinetic properties before describing many clinical trials that support its use as a safe and effective tool in the palliation of patients with bone metastases.
authors: Department of Radiation Oncology, Medical College of wisconsin, Milwaukee, WI, USA.
authors: John
authors: J
authors: Longo
authors: Stephen
authors: S
authors: Lutz
authors: Candice
authors: C
authors: Johnstone
keywords: bone metastases; pain; pain flare; radiopharmaceuticals
references: J Clin Oncol. 2002 Jan 1;20(1):189-96
references: 11773169
references: J Nucl Med. 1993 Nov;34(11):1839-44
references: 8229221
references: Ann Oncol. 2012 Jul;23(7):1899-905
references: 22104576
references: Radiother Oncol. 2005 Jun;75(3):258-70
references: 16299924
references: Cancer. 2000 Jun 15;88(12 Suppl):2934-9
references: 10898337
references: Eur J Cancer. 2012 Mar;48(5):678-86
references: 22341993
references: Eur J Nucl Med. 1999 Jan;26(1):2-7
references: 9933654
references: Eur J Cancer. 1997 Sep;33(10):1583-91
references: 9389919
references: Curr Opin Support Palliat Care. 2012 Sep;6(3):310-5
references: 22710580
references: J Nucl Med. 1990 May;31(5):586-93
references: 2341893
references: Q J Nucl Med Mol Imaging. 2011 Aug;55(4):431-47
references: 21738116
references: J Clin Oncol. 2009 May 20;27(15):2436-42
references: 19364960
references: J Clin Oncol. 1998 Apr;16(4):1574-81
references: 9552068
references: Lancet Oncol. 2005 Jun;6(6):392-400
references: 15925817
references: Cochrane Database Syst Rev. 2011 Jul 06;(7):CD003347
references: 21735393
references: J Nucl Med. 1993 Jul;34(7):1031-6
references: 7686217
references: Semin Radiat Oncol. 2000 Apr;10(2):103-14
references: 10727599
references: Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):965-76
references: 21277118
references: J Nucl Med. 1989 Nov;30(11):1814-8
references: 2478681
references: J Clin Oncol. 2009 May 20;27(15):2429-35
references: 19364971
references: Urology. 2004 May;63(5):940-5
references: 15134985
references: J Nucl Med. 1990 Aug;31(8):1316-25
references: 2384798
references: Rev Urol. 2004;6 Suppl 10:S3-S12
references: 16985930
references: Urol Oncol. 2011 Nov-Dec;29(6):670-5
references: 19962920
references: Cancer. 2007 Feb 1;109(3):637-43
references: 17167764
references: J Palliat Med. 2009 May;12(5):417-26
references: 19416037
references: Clin Genitourin Cancer. 2013 Mar;11(1):20-6
references: 23021204
references: J Nucl Med. 1992 Aug;33(8):1451-8
references: 1378887